Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2016

View Archived Issues

Biallelic mutations in REV7 gene are associated with Fanconi anemia

Galecto Biotech patents galectin 3 ligands

Novel AR antagonists show promising activity in castration resistant prostate cancer

Akers Biosciences presents results for OxiCheck disposable breath test

Auris Medical's phase III trial of Keylizen does not meet its two coprimary efficacy endpoints

Xenetic Biosciences starts collaboration with Excivion to develop Zika vaccine

Hybrid CB1/iNOS antagonist ameliorates liver fibrosis in preclinical models

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Ambrx's IND for ARX-788 becomes active

Aclaris Therapeutics reports data from WART-201 phase II trial

NIH grants support work at Feinstein Institute on bioelectronic medicine and sepsis

Mayne Pharma acquires dermatology-related assets from GlaxoSmithKline

NIAID funding supports testing of Kineta's broad-spectrum antivirals in preclinical Zika models

Intellia presents preclinical data on in vivo gene editing with LNPs to deliver CRISPR/Cas9

Kancera describes ROR1 inhibitors

Bayer Healthcare develops sGC activators

Experimental inhibition of S100P gene reverses trastuzumab resistance in breast cancer

Kadimastem signs agreement with unnamed medical device company for diabetes-related device

Physiomics signs share purchase agreement with BioMoti

Chinese clinical trial authorization for TaiGen's furaprevir

Michael James Enterprises begins research on new dronabinol-based formulation for anorexia nervosa

Juniper Pharmaceuticals completes phase IIb trial of COL-1077

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.